ClinicalTrials.gg
CompletedNCT03303976Updated Dec 4, 2018

Phase I to Test a New Pneumococcal Vaccine

A Phase 1 interventional study of Bioconjugate pneumococcal vaccine and Multivalent plain polysaccharide vaccine in Pneumococcal Pneumonia and Pneumonia, Bacterial, sponsored by LimmaTech Biologics AG. Completed at 1 site in Germany. Open to participants aged 60 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-04.

Sponsored by LimmaTech Biologics AG · Phase 1, Interventional, and Prevention

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
60 Years to 70 Years
Sex
All
01

Study summary

To obtain first-in-human data on a new candidate vaccine against Streptococcus pneumoniae in healthy adult and elderly volunteers.

The study aims to assess the safety and immunogenicity of a bioconjugate investigational vaccine compared to the control group (Pneumovax23).

Read the detailed description

The study aims to assess the safety and immunogenicity of a new bioconjugate investigational vaccine compared to the control group (Pneumovax23) in a randomised, staggered, 2-steps controlled trial.

02

Conditions studied

  • Pneumococcal Pneumonia
  • Pneumonia, Bacterial

Keywords

  • pneumococcal vaccine
  • bioconjugate
03

In context

Pneumonia, Pneumococcal

44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.

This study's enrollment of 72 is below the median of 388 across 37 interventional studies indexed under Pneumonia, Pneumococcal.

Browse Pneumonia, Pneumococcal studies →

Lead sponsor

LimmaTech Biologics AG is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 60 and 70 (inclusive) years of age at the time of vaccination.
  • Subject who is willing and able to comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
  • Signed obtained from the subject.

Exclusion criteria

Exclusion Criteria:

  • Health condition that, in the opinion of the investigator, may interfere with optimal participation in the study or place the volunteer at increased risk of adverse events (AEs). Study clinicians, in consultation with the principal investigator, will use clinical judgment on a case-by-case basis to assess safety risks under this criterion. The PI will consult with the medical monitor as appropriate. • abnormalities on physical examination.
  • Clinically significant abnormalities on laboratory screening.
  • Acute or chronic, clinically significant cardiovascular, pulmonary, hepatic or renal abnormality, diseases and/or insufficiency as determined by physical examination or laboratory tests, in particular: unstable current or history of coronary artery disease or cardiac insufficiency, uncontrolled hypertension, clinically significant history of myocardial infarction, atrial fibrillation, uncontrolled or clinically significant type 2 diabetes, current or history of rheumatoid arthritis or temporal arteritis, current acute or chronic active pulmonary diseases.
  • Planned administration of a vaccine not foreseen by the study protocol within 4 weeks before and after the vaccination.
  • Previous vaccination with any licensed or pneumococcal vaccine or planned administration of a pneumococcal vaccination not foreseen by the study protocol and during the study period, as reported by subject.
  • History of radiologically documented pneumonia or invasive pneumococcal disease (IPD) within 3 years previous to study start, as reported by subject.
  • Known to any components of the pneumococcal conjugate vaccine.
  • Previous vaccination with any pseudomonas investigational vaccine as reported by the subject.
  • Known or suspected impairment of immunological function, documented (HIV) infection, asplenia, or history of disease.
  • History of regular use (>2 weeks) in the last 6 months of drugs including systemic (e.g. corticosteroids ≥0.5 mg/kg BW/day, excluding inhaled and topical steroid).
  • Has a coagulation disorder contraindicating intramuscular vaccination..
  • Received or receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation or autoimmune disease.
  • Received a blood transfusion or previous treatment with blood products, including immunoglobulins within the 3 months preceding the injection, or is scheduled to receive them within 30 days after vaccination.
  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 3 months preceding the administration of study vaccine, or planned use during the study period.
  • (Body Mass Index) \<19 or ≥35.
  • Positive blood test for , virus (HCV), HIV-1/2.
  • History of allergy to any vaccine.
  • Use of any antibiotic therapy within 1 week preceding injection.
  • Subjects with an elective surgical intervention, planned during the study period.
  • History of chronic alcohol consumption and/or drug abuse.
  • Blood donation of at least 500 mL blood draw within 3 months preceding injection or planned during the study period as reported by subject.
  • Pregnancy or intention to become pregnant as reported by subject.
  • Female subjects who are not for at least 2 years.
  • Man subjects with a female partner in reproductive age refusing to use methods.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Pneumo1-low dose

    Arm A: intramuscular injection monovalent bioconjugate pneumococcal vaccine

    Biological: Bioconjugate pneumococcal vaccine

  • Experimental
    Pneumo1-mid dose

    Arm B: intramuscular injection monovalent bioconjugate pneumococcal vaccine

    Biological: Bioconjugate pneumococcal vaccine

  • Experimental
    Pneumo1-target dose

    Arm C: intramuscular injection monovalent bioconjugate pneumococcal vaccine

    Biological: Bioconjugate pneumococcal vaccine

  • Active comparator
    Pneumovax23

    Arm D: intramuscular injection multivalent plain polysaccharide vaccine

    Biological: Multivalent plain polysaccharide vaccine

Interventions

  • BiologicalBioconjugate pneumococcal vaccine

    Bioconjuagte vaccine against bacterial pneumococcal infection

  • BiologicalMultivalent plain polysaccharide vaccine

    Multivalent plain polysaccharide vaccine against bacterial pneumococcal infection

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Safety and tolerability of the candidate vaccine as determined by occurrence, severity, relationship, of solicited and unsolicited advers events (AEs) and serious adverse events (SAEs) after injection of the candidate vaccine compared to the control group throughout the study until one month after injection.

    Time frame: until one month after injection

Secondary outcomes

  1. Clinical laboratory abnormality measure

    Safety of the candidate vaccine by measuring changes in haematological and biochemical safety parameters before injection (baseline) and after vaccine administration, in terms of absolute changes and between groups.

    Time frame: change from baseline one week after injection and one month after injection

  2. Assess immunogenicity of the candidate vaccine

    Evaluation of antigen-specific antibodies levels and functionality at each time point for all groups in terms of change from baseline

    Time frame: one month and six months after injection

07

Study locations

1 site
  • CRS
    Mönchengladbach, Germany
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03303976
Lead sponsor
LimmaTech Biologics AG
Responsible party
Sponsor
First posted
Oct 6, 2017
Start date
Sep 7, 2017
Primary completion
Sep 12, 2018
Completion
Sep 12, 2018
Last update
Dec 4, 2018

Study contacts

Michael Leidig, MD
principal investigator · CRS Mönchengladbach

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion